The Bureau of Industry and Security is accepting through Dec. 10 comments on potential export controls on brain-computer interface technology. For more information, please contact attorney Kristine Pirnia via email.

According to BIS, BCI frequently involves a process in which brain signals are acquired, analyzed, and then translated into commands that are used to control machines, potentially transferred to other humans, or used for human assessment or enhancement. Medical uses of BCI technology include replacing or restoring useful function to people disabled by neuromuscular disorders. BCI technology can also be a promising interaction tool for the public, with many potential applications in multimedia, entertainment, and other fields. Further, this technology will also have potential for military use in enhancing the capabilities of human soldiers, including collaboration for improved decision making, assisted-human operations, and advanced manned and unmanned military operations.

BIS is seeking input on (1) the potential uses of BCI technology, particularly with respect to its impact on U.S. national security (e.g., whether such technology could provide the U.S. or any of its adversaries with a qualitative military or intelligence advantage), and (2) how to ensure that the scope of any export controls that may be imposed on this technology would be effective (in terms of protecting U.S. national security interests) and appropriate (with respect to minimizing their potential impact on legitimate commercial or scientific applications).

Copyright © 2024 Sandler, Travis & Rosenberg, P.A.; WorldTrade Interactive, Inc. All rights reserved.

ST&R: International Trade Law & Policy

Since 1977, we have set the standard for international trade lawyers and consultants, providing comprehensive and effective customs, import and export services to clients worldwide.

View Our Services 


Cookie Consent

We have updated our Privacy Policy relating to our use of cookies on our website and the sharing of information. By continuing to use our website or subscribe to our publications, you agree to the Privacy Policy and Terms & Conditions.